LPL Financial LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 11.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,800 shares of the biotechnology company’s stock after buying an additional 1,879 shares during the quarter. LPL Financial LLC’s holdings in Repligen were worth $2,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in the company. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Repligen by 120.0% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 209 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 114 shares during the last quarter. Fortis Capital Advisors LLC acquired a new stake in Repligen in the 4th quarter worth approximately $35,000. Clearstead Advisors LLC acquired a new stake in Repligen in the 1st quarter worth approximately $38,000. BOKF NA acquired a new stake in Repligen in the 1st quarter worth approximately $42,000. Finally, V Square Quantitative Management LLC acquired a new stake in Repligen in the 2nd quarter worth approximately $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Repligen
In other Repligen news, Director Karen A. Dawes sold 850 shares of Repligen stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $171.38, for a total transaction of $145,673.00. Following the completion of the transaction, the director now directly owns 83,741 shares of the company’s stock, valued at $14,351,532.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.10% of the company’s stock.
Repligen Stock Performance
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.09. The company had revenue of $141.20 million during the quarter, compared to analysts’ expectations of $140.68 million. Repligen had a return on equity of 6.08% and a net margin of 17.29%. The business’s revenue was down 29.6% on a year-over-year basis. During the same period last year, the business earned $0.77 earnings per share. Analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.
Analyst Ratings Changes
RGEN has been the subject of several analyst reports. UBS Group reduced their target price on Repligen from $210.00 to $170.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. StockNews.com started coverage on Repligen in a research report on Thursday, October 5th. They issued a “sell” rating for the company. Stephens increased their price objective on Repligen from $180.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, August 3rd. KeyCorp reduced their price objective on Repligen from $240.00 to $210.00 and set an “overweight” rating for the company in a research report on Wednesday, November 1st. Finally, Royal Bank of Canada reduced their price objective on Repligen from $207.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, November 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.55.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Five stocks we like better than Repligen
- What is a Mid Cap Stock? How to Invest
- Institutional activity provides a bottom for gaming stocks
- How to Invest in the Entertainment Industry
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- What Does Downgrade Mean in Investing?
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.